The role of somatostatin analogues in the treatment of neuroendocrine tumours

Grozinsky‐Glasberg, Simona; Grossman, Ashley; Korbonits, Márta

doi:10.1016/j.mce.2007.10.006

Cited by 51 publications

(29 citation statements)

References 161 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 'classical' clinically available SSA octreotide and lanreotide, with a preferential binding affinity for sst 2 , at standard dosages have been demonstrated to improve the symptoms related to functioning NET in 64% of patients, with a biochemical response in 66% of cases (Grozinsky-Glasberg et al 2008). Only in about 10% of cases there is a significant reduction of tumor mass, while tumor stabilization occurs in 35-50% of patients (Grozinsky-Glasberg et al Table 1) focusing on SSTR and D 2 receptor co-expression in a number of neuroendocrine neoplasms, such as GEP and lung NET, and non-endocrine tumors.…”

Section: Ss and Da Analogs Treatment In Endocrine Tumorsmentioning

confidence: 99%

The role of somatostatin and dopamine D2 receptors in endocrine tumors

Gatto¹,

Hofland²

2011

Endocrine-Related Cancer

View full text Add to dashboard Cite

Somatostatin (SS) and dopamine (DA) receptors have been highlighted as two critical regulators in the negative control of hormonal secretion in a wide group of human endocrine tumors. Both families of receptors belong to the superfamily of G protein-coupled receptors and share a number of structural and functional characteristics. Because of the generally reported high expression of somatostatin receptors (SSTRs) in neuroendocrine tumors (NET), somatostatin analogs (SSA) have a pronounced role in the medical therapy for this class of tumors, especially pituitary adenomas and well-differentiated gastroenteropancreatic NET (GEP NET). Moreover, NET express not only SSTR but also frequently dopamine receptors (DRs), and DA agonists targeting the D 2 receptor (D 2 ) have been demonstrated to be effective in controlling hormone secretion and cell proliferation in in vivo and in vitro studies. The treatment with SSAs combined with DA agonists has already been demonstrated efficacious in a subgroup of patients with GH-secreting pituitary adenomas and few reported cases of carcinoids. The recent availability of new selective and universal SSA and DA agonists, as well as the chimeric SS/DA compounds, may shed new light on the potential role of SSTR and D 2 as combined targets for biotherapy in NET. This review provides an overview of the latest studies evaluating the expression of SSTR and DR in NET, focusing on their co-expression and the possible clinical implications of such co-expression. Moreover, the most recent insights in SSTR and D 2 pathophysiology and the future perspectives for treatment with SSA, DA agonists, and SS/DA chimeric compounds are discussed.

show abstract

Section: Ss and Da Analogs Treatment In Endocrine Tumorsmentioning

confidence: 99%

The role of somatostatin and dopamine D2 receptors in endocrine tumors

Gatto¹,

Hofland²

2011

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…[31][32][33] In view of the new era of chimeric somatostatin-dopamine drugs, this combination may prove to be of interest in the management of NETs expressing dopamine receptors. 18 In summary, the high expression of D 2 dopamine receptors in NETs, shown by the study of Grossrubatscher et al provides new insights on the pathophysiology of NETs and should prompt molecular studies to better address the pathways involved in the high D 2 immunoexpression found in these tumors.…”

Section: Commentarymentioning

confidence: 99%

The potential role of D2 dopamine receptors as a target in the management of neuroendocrine tumors

Ribeiro‐Oliveira

Korbonits²,

Grossman³

2008

Cancer Biology & Therapy

Self Cite

View full text Add to dashboard Cite

“…The presence of somatostatin receptors is the basis for the subsequent treatment with 'cold' somatostatin analogues. Given the low response rate to this treatment, in the range of 5-7%, a new therapeutic approach using somatostatin analogues radio-labelled with suitable isotopes has been developed [49,51].…”

Section: Receptor Radionuclide Therapy Of Liver Metastases From Neuromentioning

confidence: 99%

Institutional guidelines and ongoing studies in management of liver tumours: the experience of the European Institute of Oncology

Biffi¹,

Orsi²,

Zampino³

et al. 2008

ecancer

View full text Add to dashboard Cite

Background: An institutional task force on upper gastrointestinal tumours is active at the European Institute of Oncology (EIO). Members decided to collate the institutional guidelines on management of liver tumours (primary and metastatic) into a document. This article is aimed at presenting the current treatment guidelines as well as ongoing research protocols and trials in this field at the EIO. Methods: A steering committee convened to assign tasks to individual members. Contributions from experts in each treatment area were collated in a single document, in order to produce a draft for subsequent review from the aforementioned committee. Six drafts have been discussed and the final version approved. Results: Surgical, medical oncology, interventional radiology, nuclear medicine and radiation therapy approaches, their roles in management of liver tumours and ongoing research trials are presented and discussed in this article. Conclusions: At the EIO a multi-disciplinary integrated approach to liver tumours is standard and several ongoing research projects are currently active in this field.

show abstract

The role of somatostatin analogues in the treatment of neuroendocrine tumours

Cited by 51 publications

References 161 publications

The role of somatostatin and dopamine D2 receptors in endocrine tumors

The role of somatostatin and dopamine D2 receptors in endocrine tumors

The potential role of D2 dopamine receptors as a target in the management of neuroendocrine tumors

Institutional guidelines and ongoing studies in management of liver tumours: the experience of the European Institute of Oncology

Contact Info

Product

Resources

About